ArticleHaematologica2024

Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.

Koh Izumiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.